Delivery Order SPE2DB20D3111-SPE2DB24FA8TR

Award Date 8/20/24
Potential Completion Date 8/21/24
Potential Value $2.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,908.02 firm fixed-price delivery order is for the supply of Olumiant 2 mg tablets, a medication used to treat certain autoimmune conditions. The contract has an ultimate completion date of March 14, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Olumiant 2 mg tablets. The $3,111.94 firm-fixed-price contract has a completion date of September 10, 2024. The award is not associated with a set-aside program. This order is likely part of AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 through December 2025, to...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a firm fixed price of $12,956.25 and covers the supply of Olumiant 2 mg tablets to support military healthcare programs. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,095.74 firm fixed-price delivery order is for Olumiant 2 mg tablets and is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and...
This federal contract award is for a delivery order placed by the Defense Logistics Agency (DLA) with AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Olumiant 4 mg tablets. The contract has a ceiling value of $13,507.38 and a completion date of May 7, 2024. It is a firm fixed-price contract, without a set-aside designation. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp for the delivery of Olumiant 4 mg tablets. The $13,244.23 firm fixed-price delivery order has a completion date of July 8, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support...
This federal contract award, with ID SPE2DB22D2214|SPE2DB25FS4PN, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is not set aside, has a ceiling value of $41,565.55 and is a delivery order for the supply of the medication Olumiant 4 mg tablet in 30-count packaging. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $24,701.59, is for the supply of Olumiant 4 mg tablets to support federal healthcare programs. The contract has an ultimate completion date of October 25, 2024 and is a firm fixed-price delivery order. This award is not designated as a set-aside contract. Amerisourcebergen holds a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,870.12, is to provide 4,568,082,666 tablets of the medication Olumiant 2 mg. The delivery order has an ultimate completion date of May 1, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that AmerisourceBergen holds with the DLA Troop...
This federal contract award, valued at $2,502.75, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a total potential value of $999,999,999 and runs through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products...
  • SPE2DB20D3111
    Indefinite Delivery Contract
  • SPE2DB20D3111-SPE2DB24FA8TR
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract, valued at $2,911.17, is for the delivery of the prescription medication Olumiant 2 mg tablets. It is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025. This IDC enables the DLA to efficiently procure a wide range of medical commodities, including pharmaceuticals and supplies, to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and is expected to be completed by August 21, 2024.

Generated 11/19/24, 9:33 AM